<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03116113</url>
  </required_header>
  <id_info>
    <org_study_id>NSR-RPGR-01</org_study_id>
    <nct_id>NCT03116113</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa</brief_title>
  <acronym>XIRIUS</acronym>
  <official_title>A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nightstar Therapeutics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nightstar Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial of AAV-RPGR retinal gene therapy for patients with X-linked retinitis
      pigmentosa
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with a DLT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients with a TEAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in best corrected visual acuity (BCVA) from baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>BCVA will be assessed at each visit using the Early Treatment Diabetic Retinopathy Study (EDTRS) protocol. Missing post-baseline values will be imputed using last observation carried forward (LOCF) method.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>X-Linked Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Low dose AAV-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of a single low dose range AAV-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose AAV-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of a single medium dose range AAV-RPGR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose AAV-RPGR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, subretinal administration of a single high dose range AAV-RPGR</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV-RPGR</intervention_name>
    <description>Comparison of different dosages of AAV-RPGR</description>
    <arm_group_label>Low dose AAV-RPGR</arm_group_label>
    <arm_group_label>Medium dose AAV-RPGR</arm_group_label>
    <arm_group_label>High dose AAV-RPGR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          -  male

          -  &gt;= 18 years of age

          -  have a genetically confirmed diagnosis of X-linked retinitis pigmentosa

        Key exclusion Criteria:

          -  participated in a gene therapy trial previously or a clinical trial with an
             investigational drug in the past 12 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Nightstar Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NightstaRx</last_name>
    <phone>+44 207 611 2077</phone>
    <email>enquiries@nightstarx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manchester Royal Eye Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford Eye Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 13, 2017</last_update_submitted>
  <last_update_submitted_qc>April 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

